Newsletter | January 15, 2025

01.15.25 -- Inside Interius' Global Regulatory Strategy

SPONSOR

A Full-Service Solution Partner Disrupting the Outsourcing Paradigm

inSeption Group offers a full-service solution designed to disrupt the current outsourcing paradigm, resurrecting a common-sense approach to rebuild business trust and confidence in a client’s selected vendor. Primarily focused on oncology, hematology, neurodegenerative disorders, and rare/orphan disease indications, with a specialization in cell and gene therapy, inSeption has been a solution for its’ clients who have experienced the progressive degradation of today’s outsourcing options. Contact them.

FEATURED ARTICLE

Inside Interius' Global Regulatory Strategy

Interius BioTherapeutics' lentiviral gene therapy INT2104, which creates CAR T and CAR NK cells in vivo, headed to clinical trials in Australia where the company dosed a first patient with a B-cell malignancy. CEO Phil Johnson, M.D. gave us a look inside the company's global regulatory strategy.

INDUSTRY INSIGHTS

The Crucial Role Of Mobile Visits In A DCT For Interstitial Lung Disease

Decentralized clinical trials (DCTs) are revolutionizing patient participation by bringing clinical research directly to participants' homes through mobile research nurses.

Defining And Implementing The Right Oncology Digital Strategy

A panel of oncology experts shares how top life science companies are using a combination of DHTs, ePROs, clinical trial platforms, and more to ease oncology research and drastically reduce timelines.

The Evolution Of Communication In Healthcare And Clinical Trials

Educational animation in clinical trials enhances patient understanding, health literacy, and retention, addressing diverse literacy needs by simplifying complex information into engaging visual content.

The Next Frontier: Industrializing Cell Therapy Manufacturing

Learn how leveraging platform processes can enable flexible service at each level – pre-clinical through commercial – and reduce development timelines and costs on the path to market.

The Flux Performance Of Nanoformed And Untreated PRX Solid Suspensions

Explore the application of in vitro flux assays to nanoparticles, with data on how the in vitro permeability apparatus can characterize the membrane flux performance of an API formulated as a nanosuspension.

NEW PODCAST EPISODE

RNA Sandbox with Johns Hopkins RNA Innovation Center's Jeff Coller, Ph.D. and Michelle Kim, Ph.D.

Don’t miss this week’s Business of Biotech podcast! We’re joined by Drs. Jeff Coller and Michelle Kim, along with Advancing RNA’s Anna Rose Welch, to discuss the Johns Hopkins University RNA Innovation Center. Learn how this groundbreaking venture supports RNA developers and aspiring business builders with unique resources and opportunities. Tune in to discover the Center’s origins, offerings, and how it’s shaping the future of RNA innovation.